翟晓晨#,张梅芳#,武娟,等.初探氨来呫诺抑制TBK1活性与其临床副作用的关系[J].中国海洋药物,2024,43(4):73-79.
初探氨来呫诺抑制TBK1活性与其临床副作用的关系
Preliminary Exploring of the Relationship Between the Inhibition of TBK1 by Amelexanox and Its Clinical Side Impact
投稿时间:2023-03-22  修订日期:2023-05-20
DOI:10.13400/j.cnki.cjmd.2024.04.010
中文关键词:  氨来呫诺,海洋化合物,海洋Halomonas sp.,TBK1,安全药理学研究
English Keywords:Amlexanox, Marine  compound, Marine  Halomonas sp., TBK1, Safety  pharmacology research
Fund Project:
作者单位E-mail
翟晓晨# 中国海洋大学 15954764302@163.com 
张梅芳# 中国海洋大学 zhangmeifang96@163.com 
武娟 青岛海洋生物医药研究院 海洋创新药物药筛选与评价中心 932837429@qq.com 
杜凯欣 中国海洋大学 海洋药物教育部重点实验室 echo040100@sina.com 
王鑫* 中国海洋大学 海洋药物教育部重点实验室 xinwangPharm@hainanu.edu.cn 
摘要点击次数: 8745
全文下载次数: 1
中文摘要:
      目的 消炎药氨来呫诺是一类海洋盐单胞菌代谢产物的结构类似物,临床使用时有上呼吸道感染概率上升的风险,可能与免疫抑制相关。本研究以氨来呫诺为例,探索该类化合物抑制TBK1活性对天然免疫的影响及与临床副作用的潜在关联。 方法 运用分子生物学和病毒学手段,在细胞和动物模型中,评估氨来呫诺对病原体感染及相关炎症通路的影响。结果 氨来呫诺及其类似物是潜在的TBK1抑制剂;氨来呫诺不显著抑制机体对病原体刺激的应答;以氨来呫诺为代表的三环胺类结构化合物抑制TBK1 (TANK-binding kinase 1)活性可能不直接导致感染概率上升。
English Summary:
      Objective Amlexanox, an anti-inflammatory drug, is the analogue of a class of Halomonas sp. metabolites. Amlexanox increases the incidence of upper respiratory tract infection in the clinic, possibly related to immunosuppression. We studied amlexanox as an example to explore the effects of this kind of compound on innate immunity by inhibiting TBK1 activity and its potential association with clinical side effects. Methods The effects of amlexanox on pathogenic infections and associated inflammatory pathways were evaluated in cell and animal models utilizing molecular biology and virology. Results Amlexanox and its analogues Marine Halomonas sp. metabolites were potent inhibitors of TBK1. Amlexanox did not significantly inhibit the immune responses to pathogen stimuli. Tricyclic amine structural compounds represented by amlexanox inhibited TBK1(TANK-binding kinase 1) activity and probably did not directly increase infection probability.
查看全文  查看/发表评论  下载PDF阅读器
关闭